Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women

Cancer Detection and Prevention

Volumn 27, Issue 2, 2003, Pages 116-121

  Ali, M Aktar ^a   Akhmedkhanov, Arslan ^a,b   Zeleniuch Jaquotte, Anne ^a   Toniolo, Paolo ^a,b   Frenkel, Krystyna ^a   Huang, Xi ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dept of Obstetrics and Gynecology ^*  (United States)

Author keywords

Ferritin; Nitrite; Reliability; Renal cancer; Serum iron

Indexed keywords

EID: 0037260842     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(03)00027-8     Document Type: Article

References (38)

1. Ries LAG, Kosary CL, Hankey BF, et al. SEER Cancer statistics review, 1973-1994: tables and graphs. NIH Publication no. 97-2789. Bethesda (MD): National Cancer Institute; 1997.
2. Gago-Dominguez M, Castelao JE, Yuan JM, et al. Increased risk of renal cell carcinoma subsequent to hysterectomy. Cancer Epidemiol Biomarkers Prev 1999;8:999-1003.
3. American Cancer Society. Cancer facts & figures - 2001. Atlanta (GA): American Cancer Society, Inc.; 2001. p. 5.
4. Dhote R, Pellicer-Coeuret M, Thiounn N, et al. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 2000;86:20-7.
5. Chow WH, Gridley G, Fraumeni Jr JF, et al. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343:1305-11.
6. Van Poppel H, Nilsson S, Algaba F, et al. Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl 2000;136-65.
7. Yuan JM, Castelao JE, Gago-Dominguez M, et al. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 1998;77:1508-13.
8. Pesch B, Haerting J, Ranft U, et al. Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. Int J Epidemiol 2000;29:1014-24.
9. Parent ME, Hua Y, Siemiatycki J. Occupational risk factors for renal cell carcinoma in Montreal. Am J Ind Med 2000;38:609-18.
10. Heath Jr CW, Lally CA, Calle EE, et al. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997;145:607-13.
11. Godley PA, Stinchcombe TE. Renal cell carcinoma. Curr Opin Oncol 1999;11:213-7.
12. Johnson S. Iron catalyzed oxidative damage, in spite of normal ferritin and transferrin saturation levels and its possible role in Werner's syndrome, Parkinson's disease, cancer, gout, rheumatoid arthritis, etc. Med Hypotheses 2000;55:242-4.
13. Nelson RL. Dietary iron and colorectal cancer risk. Free Radic Biol Med 1992;12:161-8.
14. Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-82.
15. Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-52.
16. Selby JV, Friedman GD. Epidemiologic evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988;41:677-82.
17. Tseng M, Sandler RS, Greenberg ER, et al. Dietary iron and recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997;6:1029-32.
18. Kato I, Dnistrian AM, Schwartz M. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 1999;80:693-8.
19. Worwood M. The laboratory assessment of iron status - an update. Clin Chim Acta 1997;259:3-23.
20. Wurzelmann JI, Silver A, Schreinemachers DM, et al. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1996;5:503-7.
21. Bird CL, Witte JS, Swendseid ME, et al. Plasma ferritin, iron intake, and the risk of colorectal polyps. Am J Epidemiol 1996;144:34-41.
22. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992;267:18148-53.
23. Garner B, Roberg K, Brunk UT. Endogenous ferritin protects cells with iron-laden lysosomes against oxidative stress. Free Radic Res 1998;29:103-14.
24. Jansson OT, Morcos E, Brundin L, et al. Nitric oxide synthase activity in human renal cell carcinoma. J Urol 1998;160:556-60.
25. Toniolo P, Levitz M, Zeleniuch-Jaquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
26. Zeleniuch-Jaquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-81.
27. Kato I, Akhmedkhanov A, Koenig K, et al. Prospective study of diet and female colorectal cancer: the New York University Women's Health Study. Nutr Cancer 1997;28:276-81.
28. Fang R, Aust AE. Induction of ferritin synthesis in human lung epithelial cells treated with crocidolite asbestos. Arch Biochem Biophys 1997;340:369-75.
29. Ding AH, Nathan CF, Stuehr DJ, et al. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.
30. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-8.
31. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
32. Akiba S, Neriishi K, Blot WJ, et al. Serum ferritin and stomach cancer risk among a Japanese population. Cancer 1991;67:1707-12.
33. Miyata Y, Koga S, Nishikido M, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001;58:161-4.
34. Ozen H, Uygur C, Sahin A, et al. Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995;46:494-8.
35. Kirkali Z, Esen AA, Kirkali G, et al. Ferritin: a tumor marker expressed by renal cell carcinoma. Eur Urol 1995;28:131-4.
36. Partin AW, Criley SR, Steiner MS, et al. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. Urology 1995;45:211-7.
37. Kilbourn RG, Fonseca GA, Griffith OW, et al. N-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 1995;23:1018-24.
38. Fishman M, Seigne J, Antonia S. Novel therapies for renal cell carcinoma. Expert Opin Investig Drugs 2001;10:1033-44.